1.Radioprotective effect of cimitidine on acutely irradiated mice survival and hematopoietic system
Qingrong WANG ; Junling ZHANG ; Ying HE ; Xianrong SHEN ; Dingwen JIANG ; Dengyong HOU ; Yuming LIU ; Wei CHEN ; Kexian LI ; Qiong LIU ; Qun LUO
Medical Journal of Chinese People's Liberation Army 2017;42(1):61-65
Objective To investigate the radioprotective effect of cimetidine on survival rate and hematopoietic system in acutely irradiated mice.Methods The total body irradiation doses were 6.0Gy and 8.0Gy respectively at 1.01Gy/min rate. Sixty healthy male C57BL/6 mice were randomly divided into control group, model group, positive-drug (523) group and cimetidine groups (33.3mg/kg, 100mg/kg and 300mg/kg). Each group had ten mice. The mice were given intragastric administration of cimetidine for 6d before the irradiation in cimetidine groups, and 523 was administered before irradiation once a day for one day in 523 group, and at 5h after irradiation, was given again. The 30d survival rate after 8.0Gy irradiation was recorded. The peripheral blood cells, bone marrow DNA content and frequency of micronucleated polychromatic erythrocytes (fMNPCE) were determined 30d after 6.0Gy irradiation.Results After 8.0Gy irradiation, all the mice died on 21th day in model control group. The survival rates in cimetidine groups were 50%, 20% and 30%, respectively. After 6.0Gy irradiation on 30th day, compared with control group, the peripheral white blood cells (WBC) and bone marrow DNA content were decreased significantly (P<0.01,P<0.05) in model group, and fMNPCE was increased significantly (P<0.05). Compared with model group, WBC was significantly increased in 300mg/kg cimetidine group (P<0.01). In cimetidine groups, the bone marrow DNA content was increased significantly after irradiation (P<0.01 orP<0.05), and the fMNPCE was decreased significantly (P<0.01 orP<0.05) and tended towards normal.Conclusion Cimetidine could improve 30d survival rate of acutely irradiated mice and has good protective effect on hematopoietic system.
2.A Meta-analysis on effectiveness of different surgical procedures in treating esophageal variceal bleeding in patients with portal hypertension
Yi TAN ; Mingjie DONG ; Kai ZHU ; Zheng LU ; Peiyuan CUI ; Hua WU ; Binquan WU ; Wei WU ; Xiang MA ; Wanliang SUN ; Dengyong ZHANG
Chinese Journal of Hepatobiliary Surgery 2017;23(4):230-234
Objective To compare the effectiveness of surgical procedures (devascularization,shunt and combined shunt and devascularization) in treating recurrent variceal bleeding and other complications in patients with portal hypertension.Methods A systematic literature search was carried out on patients with portal hypertension,and a Meta-analysis was conducted using Revman 5.3 software to evaluate the effectiveness of different surgical procedures on recurrent esophageal variceal bleeding,hepatic encephalopathy,operative mortality and survival rates.Results A total of 24 trials were finally selected using predetermined inclusion criteria.Meta-analysis showed there was no significant difference among the three operations on operative mortality (P > 0.05).The rebleeding rate of the combined group was significantly lower than the devascularization group (P < 0.05).The encephalopathy rate of the combined group was significantly lower than the shunt group (P < 0.05),and the 1-year and 3-year survival rates of the combined group were better than the devascularization group (both P < 0.05),but there were no significant difference in the 5-year survival rates between these two groups (P > 0.18).The 1-year and 3-year survival rates were not significantly different between the combined and the shunt groups (both P > 0.05).Conclusions Combined shunt and devascularization had better therapeutic effectiveness than either devascularization alone or shunt alone in patients with portal hypertension with a high rebleeding risk.There were no significant difference among the three surgical procedures in operative mortality.The survival rates of combined surgery were significantly better than devascrlarization alone.
3.Extended hepatectomy in the treatment of type Ⅲ and Ⅳ hilar cholangiocarcinoma
Dongdong WANG ; Zheng LU ; Wei WU ; Binquan WU ; Hua WU ; Xiang MA ; Wanliang SUN ; Dengyong ZHANG ; Peiyuan CUI ; Yi TAN
Chinese Journal of Hepatobiliary Surgery 2018;24(11):761-765
Objective To study the effect of extended hepatectomy for hilar cholangiocarcinoma (HCCA) of the Bismuth-Corlette type Ⅲ and Ⅳ.Methods The clinical data of 73 patients with HCCA of the Bismuth-Corlette type Ⅲ and Ⅳ treated in our department from January,2008 to June,2016 were analyzed retrospectively.The extended hepatectomy group of patients consisted of 29 patients who underwent hepatectomy with half or more than half of the liver removed or/and combined with hepatic caudate lobectomy.The limited hepatectomy group consisted of 44 patients who underwent non-anatomical hepatectomy around the hepatic hilar region.Results Compared with the limited hepatectomy group,patients in the extended hepatectomy group had significantly longer operations with significantly more intraoperative blood loss.However,the complication rate was significantly lower than that of the limited hepatectomy group.There was no perioperative death in the extended hepatectomy group,while 3 perioperative deaths occurred in the limited hepatectomy group.The R0 resection rate was 93.1% (27 of 29) for the extended hepatectomy group,while it was 54.6% (24 of 44) for the limited hepatectomy group (P<0.05).The 1-,3-and 5-year survival rates or the extended hepatectomy group were 81.4%,51.4% and 19.3%,respectively while the corresponding rates for the limited hepatectomy group were 70.5%,24.4% and 8.7%,respectively (P<0.05).Conclusions After adequate preoperative radiological assessments on tumor resectability,and the residual liver volumes,with preoperative biliary drainage to improve liver function,extended hepatectomy effectively increased R0 resection and survival rates with improved prognosis for patients with HCCA of Bismuth-Corlette type Ⅲ and Ⅳ.
4.Effect of MSX2 interference on epithelial-mesenchymal transitions of pancreatic cancer cell line PANC-1.
Dengyong ZHANG ; Xiang MA ; Binquan WU ; Peiyuan CUI ; Huichun LIU ; Zheng LU
Journal of Southern Medical University 2015;35(2):179-184
OBJECTIVETo investigate the effect of MSX2 interference on epithelial-mesenchymal transitions (EMT) of pancreatic cancer cell line PANC-1.
METHODSThree vectors containing short hairpin RNAs (shRNAs) of MSX2 (shMSX2-1, shMSX2-2, and shMSX2-3) and the empty vector (negative control) were transfected separately into PANC-1 cell line with Lipofectamine2000. Real-time RT-PCR and Western blotting were used to observe changes in the expressions of MSX2, E-cadherin, and vimentin in the cells. CCK-8 assay was used to assess the changes in the cell growth, and wound scratch assay and Transwell assay were employed to evaluate the cell invasion and metastasis after the transfection.
RESULTSAmong the 3 shRNA, shMSX2-1 showed the highest interference efficiency. MSX2 knockdown by the specific shRNA of MSX2 significantly increased E-cadherin expressions, lowered vimentin expressions, and suppressed the invasion, metastasis and proliferation of the cells (P<0.05). MSX2 knockdown also resulted in morphological changes of the cells into cobblestone-like cells in close contact. RT-PCR results revealed significantly reduced mRNA expressions of the transcription factors snail and twist (P<0.05) without affecting slug and zeb1 expressions in the cells with MSX2 knockdown. Conclusion MSX2 knockdown can reverse EMT and induce MET in PANC1 cells, in which process the transcription factors snail and twist may play a role.
Cadherins ; metabolism ; Cell Line, Tumor ; Cell Proliferation ; Epithelial-Mesenchymal Transition ; Homeodomain Proteins ; metabolism ; Humans ; Nuclear Proteins ; metabolism ; Pancreas ; Pancreatic Neoplasms ; pathology ; RNA, Small Interfering ; Snail Family Transcription Factors ; Transcription Factors ; metabolism ; Transfection ; Twist-Related Protein 1 ; metabolism ; Vimentin ; metabolism
5. Progress of diagnosis and treatment of cholangiocarcinoma
Wei PENG ; Dengyong ZHANG ; Zheng LU
International Journal of Surgery 2020;47(2):117-122
Due to the high degree of malignancy and low surgical resection rate of cholangiocarcinoma, as well as the immaturity of postoperative adjuvant chemotherapy and targeted therapy drugs, the mortality rate of patients with cholangiocarcinoma is high and the long-term prognosis is poor. With the improvement of clinical diagnosis and treatment, preoperative evaluation and surgical technique, the diagnosis and treatment of cholangiocarcinoma have made some progress. The early stage of cholangiocarcinoma is lack of specific manifestations, so the patient has lost the opportunity of R0 resection when diagnosed. Early diagnosis can improve the patient′s R0 resection and long-term survival after surgery. The diagnostic accuracy can be improved by contrast enhanced ultrasound, enhanced magnetic resonance, positron emission tomography PET, etc. Dominated by comprehensive therapy in the treatment of bile duct carcinoma, strive for R0 resection for resectable cholangiocarcinoma, distant metastasis occurred after bile duct carcinoma can be combined with new adjuvant chemotherapy according to the review situation decides whether it is feasible to surgery, postoperative chemotherapy, molecular targeted therapy, body directional radiation therapy, and other comprehensive solutions in order to improve the long-term survival rate. This article reviews the recent progress in the pathogenesis, diagnosis and treatment of cholangiocarcinoma.
6. Effects of preoperative percutaneous transhepatic biliary drainage on surgical treatment of type Ⅲ and Ⅳ hilar cholangiocarcinoma
Dongdong WANG ; Jianzhong XU ; Qin FU ; Xiaojun FU ; Fangfang CHEN ; Zheng LU ; Jie GUO ; Xiang MA ; Wanliang SUN ; Dengyong ZHANG
Chinese Journal of Surgery 2019;57(4):288-292
Objective:
To investigate the effects of preoperative percutaneous transhepatic biliary drainage on surgical treatment of type Ⅲ and Ⅳ hilar cholangiocarcinoma.
Methods:
Clinical data of 72 patients with hilar cholangiocarcinoma of the Bismuth-Corlette type Ⅲ and Ⅳ treated at Department of General Surgery,First Affiliated Hospital of Bengbu Medical College from January 2010 to December 2017 were analyzed retrospectively.Patients were divided into two groups based on whether PTBD was performed:a drained group and an undrained group.In the drained group,there were 31 patients,20 males and 11 females,aged (59.9±9.7)years (range: 39-73 years).Among them,14 patients underwent hepatectomy with half or more than half of the liver removed (extended hepatectomy)and 17 patients underwent non-anatomical hepatectomy in the hilar region (limited hepatectomy).In the undrained group,there were 41 patients, 26 males and 15 females, aged (60.8±7.8)years(range: 45-75 years).Among them, 17 patients underwent hepatectomy with half or more than half of the liver removed (extended hepatectomy)and 24 patients underwent non-anatomical hepatectomy in the hilar region (limited hepatectomy).Percutaneous transhepatic biliary drainage(PTBD)was used in the drained group.Under the guidance of ultrasound,one or more hepatobiliary ducts could be sufficiently drained,which had good effect and was not restricted by the obstruction location of hilar cholangiocarcinoma.The analysis of the measurement data was performed using t test,and the analysis of the count data was performed using χ2 test,and the survival curve was plotted using Kaplan-meier method.
Results:
In total, 72 jaundiced patients with hilar cholangiocarcinoma underwent surgical treatment: 31 had PTBD prior to operation while 41 did not had PTBD.There were significant differences in ALT((93.2±21.4)U/L vs.(207.4±65.1)U/L),AST((87.6±18.1)U/L vs.(188.9±56.6)U/L)and total bilirubin((68.8±12.6)μmol/L vs.(227.5±87.7)μmol/L)between the patients after treatment and those before treatment(